keyword
MENU ▼
Read by QxMD icon Read
search

Mikkael Sekeres

keyword
https://www.readbyqxmd.com/read/27878822/wide-variations-in-blood-product-transfusion-practices-among-providers-who-care-for-patients-with-acute-leukemia-in-the-united-states
#1
Alexander B Pine, Eun-Ju Lee, Mikkael Sekeres, David P Steensma, Daniel Zelterman, Thomas Prebet, Amy DeZern, Rami Komrokji, Mark Litzow, Selina Luger, Richard Stone, Harry P Erba, Guillermo Garcia-Manero, Alfred I Lee, Nikolai A Podoltsev, Lisa Barbarotta, Stephanie Kasberg, Jeanne E Hendrickson, Steven D Gore, Amer M Zeidan
BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients. STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures...
November 22, 2016: Transfusion
https://www.readbyqxmd.com/read/27855285/computational-drug-treatment-simulations-on-projections-of-dysregulated-protein-networks-derived-from-the-myelodysplastic-mutanome-match-clinical-response-in-patients
#2
Leylah Drusbosky, Cindy Medina, Regina Martuscello, Kimberly E Hawkins, Myron Chang, Jatinder K Lamba, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, Mikkael A Sekeres, Mar Mallo, Francesc Sole, Rafael Bejar, Christopher R Cogle
Although the majority of MDS patients fail to achieve clinical improvement to approved therapies, some patients benefit from treatment. Predicting patient response prior to therapy would improve treatment effectiveness, avoid treatment-related adverse events and reduce healthcare costs. Three separate cohorts of MDS patients were used to simulate drug response to lenalidomide alone, hypomethylating agent (HMA) alone, or HMA plus lenalidomide. Utilizing a computational biology program, genomic abnormalities in each patient were used to create an intracellular pathway map that was then used to screen for drug response...
November 6, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27774847/differential-response-to-hypomethylating-agents-based-on-sex-a-report-on-behalf-of-the-mds-clinical-research-consortium-mds-crc
#3
Amy E DeZern, Amer M Zeidan, John Barnard, Wesley Hand, Najla Al Ali, Francis Brown, Cassie Zimmerman, Gail J Roboz, Guillermo Garcia-Manero, David P Steensma, Rami S Komrokji, Mikkael A Sekeres
First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA). Variables have not identified differential response rates between these. We assessed the influence of patient sex on outcomes including overall survival (OS) in 642 patients with higher-risk MDS treated with AZA or DAC. DAC-treated patients (35% of females, 31% of males) had marginally better OS than AZA-treated patients (p = .043), (median OS of 18.7 months versus 16.4 months), but the difference varied strongly by sex...
October 24, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27621331/myelodysplastic-syndromes-going-gently-into-that-good-night
#4
Mikkael A Sekeres
No abstract text is available yet for this article.
September 2016: Journal of Oncology Practice
https://www.readbyqxmd.com/read/27618752/precision-medicine-in-myelodysplastic-syndromes-and-leukemias-lessons-from-sequential-mutations
#5
Aziz Nazha, Mikkael A Sekeres
Precision medicine can be simply defined as the identification of personalized treatment that matches patient-specific clinical and genomic characteristics. Since the completion of the Human Genome Project in 2003, significant advances have been made in our understanding of the genetic makeup of diseases, especially cancers. The identification of somatic mutations that can drive cancer has led to the development of therapies that specifically target the abnormal proteins derived from these mutations. This has led to a paradigm shift in our treatment methodology...
September 7, 2016: Annual Review of Medicine
https://www.readbyqxmd.com/read/27538433/connect-mds-aml-design-of-the-myelodysplastic-syndromes-and-acute-myeloid-leukemia-disease-registry-a-prospective-observational-cohort-study
#6
David P Steensma, Medrdad Abedi, Rafael Bejar, Christopher R Cogle, Kathryn Foucar, Guillermo Garcia-Manero, Tracy I George, David Grinblatt, Rami Komrokji, Xiaomei Ma, Jaroslaw Maciejewski, Daniel A Pollyea, Michael R Savona, Bart Scott, Mikkael A Sekeres, Michael A Thompson, Arlene S Swern, Melissa Nifenecker, Mary M Sugrue, Harry Erba
BACKGROUND: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur primarily in older patients who are often treated outside the clinical trial setting...
August 19, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27535995/cytopenia-levels-for-aiding-establishment-of-the-diagnosis-of-myelodysplastic-syndromes
#7
Peter L Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop Kantarjian, Andrea Kuendgen, Alessandro Levis, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle M Le Beau, Marilyn L Slovak, Otto Krieger, Michael Luebbert, Jaroslaw Maciejewski, Silvia M M Magalhaes, Yasushi Miyazaki, Michael Pfeilstöcker, Mikkael Sekeres, Wolfgang R Sperr, Reinhard Stauder, Sudhir Tauro, Peter Valent, Teresa Vallespi, Arjan A van de Loosdrecht, Ulrich Germing, Detlef Haase
No abstract text is available yet for this article.
August 17, 2016: Blood
https://www.readbyqxmd.com/read/27502092/improving-prognostic-modeling-in-myelodysplastic-syndromes
#8
Aziz Nazha, Mikkael A Sekeres
Myelodysplastic syndromes (MDSs) are a heterogeneous group of disorders characterized by the accumulation of complex genetic alterations that drive disease pathogenesis and outcome. Several prognostic models have been developed over the last two decades to risk stratify patients with MDS. These models mainly used clinical variables including blast percentage, cytopenias, cytogenetics, transfusion dependency, and age. Recently, somatic mutations in specific genes have been shown to impact overall survival in MDS and can be incorporated into established prognostic models to improve their predictive abilities...
August 8, 2016: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/27489629/a-case-of-mistaken-identity-when-lupus-masquerades-as-primary-myelofibrosis
#9
Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski, Ramon V Tiu
INTRODUCTION: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocrine dysfunction, toxin/drug exposure, and connective tissue diseases, including scleroderma and systemic lupus erythematosus. Absence of clonal markers (JAK2) and heterogeneity of the symptoms often complicate the diagnosis. CASE PRESENTATION: Here, we present two cases of systemic lupus erythematosus-induced autoimmune myelofibrosis...
2013: SAGE open medical case reports
https://www.readbyqxmd.com/read/27354479/long-day-s-journey-into-night-for-lower-risk-myelodysplastic-syndromes
#10
EDITORIAL
Mikkael A Sekeres
No abstract text is available yet for this article.
September 1, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27335276/time-dependent-changes-in-mortality-and-transformation-risk-in-mds
#11
Michael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, Julie Schanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop Kantarjian, Andrea Kuendgen, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle M Le Beau, Marilyn L Slovak, Alessandro Levis, Michael Luebbert, Jaroslaw Maciejewski, Sigrid Machherndl-Spandl, Silvia M M Magalhaes, Yasushi Miyazaki, Mikkael A Sekeres, Wolfgang R Sperr, Reinhard Stauder, Sudhir Tauro, Peter Valent, Teresa Vallespi, Arjan A van de Loosdrecht, Ulrich Germing, Detlef Haase, Peter L Greenberg
In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database...
August 18, 2016: Blood
https://www.readbyqxmd.com/read/26992944/the-efficacy-of-current-prognostic-models-in-predicting-outcome-of-patients-with-myelodysplastic-syndromes-at-the-time-of-hypomethylating-agent-failure
#12
LETTER
Aziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, John Barnard, Gail J Roboz, David P Steensma, Amy E DeZern, Katrina Zell, Cassie Zimmerman, Najla Al Ali, Elias Jabbour, Molly D Greenberg, Hagop M Kantarjian, Jaroslaw P Maciejewski, Alan F List, Mikkael A Sekeres
No abstract text is available yet for this article.
June 2016: Haematologica
https://www.readbyqxmd.com/read/26968357/rigosertib-versus-best-supportive-care-for-patients-with-high-risk-myelodysplastic-syndromes-after-failure-of-hypomethylating-drugs-ontime-a-randomised-controlled-phase-3-trial
#13
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R Baer, Mikkael A Sekeres, Gail J Roboz, Gianluca Gaidano, Bart L Scott, Peter Greenberg, Uwe Platzbecker, David P Steensma, Suman Kambhampati, Karl-Anton Kreuzer, Lucy A Godley, Ehab Atallah, Robert Collins, Hagop Kantarjian, Elias Jabbour, Francois E Wilhelm, Nozar Azarnia, Lewis R Silverman
BACKGROUND: Hypomethylating drugs are the standard treatment for patients with high-risk myelodysplastic syndromes. Survival is poor after failure of these drugs; there is no approved second-line therapy. We compared the overall survival of patients receiving rigosertib and best supportive care with that of patients receiving best supportive care only in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled trial at 74 hospitals and university medical centres in the USA and Europe...
April 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26858309/a-multi-institution-phase-i-trial-of-ruxolitinib-in-patients-with-chronic-myelomonocytic-leukemia-cmml
#14
Eric Padron, Amy Dezern, Marcio Andrade-Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P Steensma, Gail J Roboz, Jeffrey E Lancet, Alan F List, Mikkael A Sekeres, Rami S Komrokji
PURPOSE: To conduct a phase I clinical trial exploring the safety and efficacy of ruxolitinib, a JAK1/2 inhibitor, for chronic myelomonocytic leukemia (CMML). EXPERIMENTAL DESIGN: Patients with CMML-1 were included without regard to previous therapy. Key exclusion criteria included an absolute neutrophil count (ANC) <0.25 × 10(3) cells/dL and a platelet count <35 × 10(3) cells/dL. Four cohorts were enrolled using a "rolling six" study design, with doses ranging from 5 to 20 mg twice daily of ruxolitinib in 5-mg dose escalations...
August 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/26799334/impact-of-allogeneic-hematopoietic-cell-transplant-in-patients-with-myeloid-neoplasms-carrying-spliceosomal-mutations
#15
Betty Ky Hamilton, Valeria Visconte, Xuefei Jia, Ali Tabarroki, Hideki Makishima, Edy Hasrouni, Donna Abounader, Matt Kalaycio, Mikkael A Sekeres, Ronald Sobecks, Hien Duong Liu, Brian Bolwell, Jaroslaw P Maciejewski, Edward Copelan, Ramon V Tiu
Molecular predictors of outcome are increasingly important in determining optimal therapy for myeloid neoplasms. Mutations in the spliceosomal genes (U2AF1 and SRSF2) predict for poor outcomes in myelodysplastic syndromes (MDS) and related diseases. We investigated the effect of hematopoietic cell transplant (HCT) on the negative prognostic impact of U2AF1 and SRSF2 mutations. In total, 122 patients with MDS (30%), acute myeloid leukemia (51%), myeloproliferative neoplasms (MPN) (11%), and MDS/MPN (8%) receiving a HCT from 2003 to 2012 were evaluated for mutations in U2AF1 and SRSF2 by direct sequencing...
June 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26777537/outcomes-of-patients-with-myelodysplastic-syndromes-who-achieve-stable-disease-after-treatment-with-hypomethylating-agents
#16
Aziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali, Gail J Roboz, David P Steensma, Amy E DeZern, Cassie Zimmerman, Elias J Jabbour, Katrina Zell, Alan F List, Hagop M Kantarjian, Jaroslaw P Maciejewski, Rami S Komrokji
Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD at 4-6 months of therapy should be offered different therapies to optimize their response or continue with the same regimen. Clinical data were obtained from the MDS Clinical Research Consortium database. SD was defined as no evidence of progression and without achievement of any other responses...
February 2016: Leukemia Research
https://www.readbyqxmd.com/read/26687424/treating-myelodysplastic-syndromes-is-more-better
#17
COMMENT
Mikkael A Sekeres
No abstract text is available yet for this article.
January 2015: Lancet Haematology
https://www.readbyqxmd.com/read/26428702/combination-therapies-for-mds-and-aml-does-one-plus-one-equal-one
#18
COMMENT
Swapna Thota, Mikkael A Sekeres
No abstract text is available yet for this article.
2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/26284571/comparing-the-prognostic-value-of-risk-stratifying-models-for-patients-with-lower-risk-myelodysplastic-syndromes-is-one-model-better
#19
COMPARATIVE STUDY
Amer M Zeidan, Mikkael A Sekeres, Xiao-Feng Wang, Najla Al Ali, Guillermo Garcia-Manero, David P Steensma, Gail Roboz, John Barnard, Eric Padron, Amy DeZern, Jaroslaw P Maciejewski, Alan F List, Rami S Komrokji
Some patients classified as having lower-risk (LR)-disease by the International Prognostic Scoring System (IPSS) fare more poorly than predicted. We examined the prognostic utility of IPSS, the MD Anderson LR-Prognostic System (LR-PSS), and the revised IPSS (IPSS-R) in a large cohort of patients classified as having IPSS LR-MDS in the MDS Clinical Research Consortium database. Actual overall survival (OS) was assessed in patients with IPSS LR-MDS (i.e. low and intermediate-1) using Kaplan-Meier methods. Harrell's c index (HCI) and Akaike information criteria (AIC) were used to compare the models...
November 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/26260295/comparing-the-prognostic-value-of-risk-stratifying-models-for-patients-with-lower-risk-myelodysplastic-syndromes-is-one-model-better
#20
Amer M Zeidan, Mikkael A Sekeres, Xiao-Feng Wang, Najla Al Ali, Guillermo Garcia-Manero, David P Steensma, Gail Roboz, John Barnard, Eric Padron, Amy Dezern, Jaroslaw P Maciejewski, Alan F List, Rami S Komrokji
Some patients classified as having lower-risk (LR)-disease by the International Prognostic Scoring System (IPSS) fare more poorly than predicted. We examined the prognostic utility of IPSS, the MD Anderson LR-Prognostic System (LR-PSS) and the revised IPSS (IPSS-R) in a large cohort of patients classified as having IPSS LR-MDS in the MDS Clinical Research Consortium database. Actual overall survival (OS) was assessed in patients with IPSS LR-MDS (i.e. low and intermediate-1) using Kaplan-Meier methods. Harrell's c index (HCI) and Akaike information criteria (AIC) were used to compare the models...
August 11, 2015: American Journal of Hematology
keyword
keyword
114088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"